Introduction
Endostatin, a potent antiangiogenic factor, is the COOHterminal 184 amino acids cleavage product of collagen XVIII. 1 This factor inhibits the growth of endothelial cells in vitro, [1] [2] [3] [4] and systemic administration of purified recombinant endostatin has been shown to inhibit the growth of established tumors and metastases in vivo. 1, 3 These experiments have demonstrated that endostatin has intrinsic antiangiogenic activities against tumors, whether primary or metastatic, suggesting that angiogenesis and growth of individual lesions are dependent upon the local balance of angiogenic and antiangiogenic factors. 5, 6 Antiangiogenic tumor therapies have recently attracted intense interest because of their broad-spectrum action, low toxicity, and absence of drug resistance. 7 However, antiangiogenic therapy in cancer patients requires prolonged administration of recombinant protein. In addition, many of these biological agents are unstable in vitro and in vivo and are difficult to produce in large quantities. 8, 9 Recent reports have shown the stable and soluble form of endostatin produced by E. coli or yeast cells. It can expand the use of endostatin. 10, 11 Gene transfer of these polypeptides represents an alternative method to deliver these agents. 12, 13 Previous studies, reported elsewhere, showed that antiangiogenic gene transfection using a viral vector as the carrier is effective to inhibit the growth of tumor in mouse models. [14] [15] [16] [17] [18] Viral vectors, however, may cause inflammation and immunological response on repeated injection, [19] [20] [21] [22] [23] and their safety issues and the toxicity may preclude their use in humans in the near future. Recently, nonviral vectors, especially cationic vectors, have been shown to be effective in mediating gene transfer. [24] [25] [26] [27] [28] Their major advantage is the lack of inflammatory reaction or immunological response; they may be repeatedly used to deliver genes in vivo. Intravenous injection of cationic vectors has been shown to be especially effective in transfecting the lung tissue. [29] [30] [31] [32] [33] [34] [35] [36] [37] In the present study, we investigated the effect of intravenous delivery of endostatin gene complexed with cationic lipid or cationic polymer on the formation of lung tumors in mice inoculated with highly metastatic fibrosarcoma cells.
Results

Secretion of endostatin after transient transfection of COS-7 cells in vitro
Mouse endostatin cDNA was inserted into a mammalian expression plasmid (pSecTag2), and the resulting plasmid was designated pST2-Endo. A diagram of the expression cassette is shown in Figure 1a .
The secretion of c-myc-His-tagged murine endostatin into the cell culture medium was investigated after transient transfection of COS-7 cells with the expression construct. Western blot analysis with anti-c-myc antibody and anti-endostatin antibody revealed that an M r 25 000 protein, the predicted molecular weight for the secreted form of endostatin, was produced and secreted into the cell culture medium (Figure 1b) Generation of stable transfectants that secrete endostatin pST2-Endo or control pST2 was transfected into murine fibrosarcoma cell line, NFSa Y83 cells. One of the endostatin-transfected NFSa Y83 clones (N-E) that secreted the expected M r 25 000 protein and one control clone (N-0) that was transfected with an empty vector were selected for further study (Figure 1c) .
Stable transfectants were examined for protein expression by immunofluorescence with anti-c-myc antibody. The endostatin-transfected clone (N-E) demonstrated cytoplasmic staining consistent with the presence of endostatin-c-myc-His fusion protein (data not shown). The control clone (N-0) or nontransfected parental NFSa Y83 cells showed only background fluorescence (data not shown).
Inhibition of lung metastatic tumor growth correlates with endostatin expression from stable transfectants
Transfection of NFSa Y83 cells by pST2-Endo or control pST2 did not change the morphology or growth characteristics of these cells in vitro (data not shown). The ability of endostatin expression to inhibit metastatic lesion growth was tested in the NFSa Y83 lung metastases model using the stable transfectants. The parental NFSa Y83 tumor cells in this well-established model produce many lung metastases after 2 weeks (Figure 2a) . We injected the same number of cells (5 Â 10 5 cells) of the stable NFSa Y83 clone (N-E) or control clone (N-0) into the tail veins of C3H mice. At 2 weeks, lungs from mice injected with N-0 cells had numerous metastases similar to the parental NFSa Y83 cells (Figure 2b ), whereas lungs from mice injected with N-E endostatin-transfected cells had obviously smaller Endostatin gene therapy on murine lung metastases model Y Nakashima et al and fewer metastases. This experiment was repeated in 10 more mice with similar results (data not shown). These data were consistent with the hypothesis that growth of metastatic lung tumor was prevented by biologically active endostatin secreted by the tumor.
Expression of exogenous endostatin mRNA in various organs after intravenous gene transfer using a quantitative RT-PCR method
We compared the expression levels of endostatin mRNA in various organs of C3H mice after intravenous injection of pST2-Endo complexed with GL67/DOPE. In our preliminary experiments, the peak levels of mRNA expression were found between 24 and 48 h after injection with the complexes (data not shown). When standardized by the expression of mouse GAPDH mRNA, the highest level of endostatin mRNA expression was found in the lung and liver, followed by the spleen, kidney and heart ( Figure 3a ). Exogenous endostatin mRNA was not detected in the lung of nontransfected mice.
Product of transfected gene detected in the cells in the lung after intravenous injection
At 24 h after intravenous injection of pST2-Endo complexed to GL67/DOPE, we evaluated the presence of transfected cells by immunohistochemistry of the whole lungs using anti-c-myc antibody under the monensin treatment to block the secretion of the synthesized protein.
Microphotographs showed that the strong signals were found in the alveolar cells ( Figure 3b ).
Staining was also seen in a variety of other cell types including endothelial cells and septal cells. The same staining pattern was obtained when PEI22K was used as a vector (data not shown). No staining was observed in lungs of nontransfected mice ( Figure 3c ). No significant histopathological abnormalities were seen in the lung of endostatin or control cationic vector-transfected animals.
Intravenous injection of endostatin gene complexed cationic vector prevents lung metastases
To investigate the effect of pST2-Endo transfection on lung metastases, endostatin gene complexed with a cationic vector was intravenously injected into mice that had inoculation of NFSa Y83 cells. A single intravenous administration of pST2-Endo or control pST2 (60 mg each) was performed on day 3 ( Figure 4 ) or day 7 ( Figure  5 ) after tumor inoculation. In control mice, microscopic nodules (o200 mm) were observed on day 3 and small nodules (o1 mm) were visible on day 7 after the tumor injection ( Figure 2a ). Two weeks after tumor inoculation, the animals were killed, and the lungs were evaluated. It was readily apparent that mice treated with pST2-Endo had fewer lung tumors than the control mice (Figures 4a and 5a). The result also showed that the number of lung metastases (Figures 4b and 5b) and the whole lung weight (Figures 4c and 5c) were significantly reduced by administration of the endostatin gene compared with the control group (98.3% or 97.6% reduction in the number of lung metastases by GL67/DOPE-or PEI22K-mediated transfection on day 3, respectively, Po0.0001 and 59.4% or 56.7% reduction in lung weight by GL67/ Endostatin gene therapy on murine lung metastases model Y Nakashima et al DOPE-or PEI22K-mediated transfection on day 3, respectively, Po0.0001; 87.5% or 87.4% reduction in the number by GL67/DOPE-or PEI22K-mediated transfection on day 7 , respectively, Po0.0001 and 56.0% or 53.0% reduction in the weight by GL67/DOPE-or PEI22K-mediated transfection on day 7, respectively, Po0.0001).
When transfection was performed on day 3, the effect was more pronounced than for the transfection on day 7 because the numbers of metastases in the groups transfected on day 3 were significantly lower than in the groups transfected on day 7 using either GL67/ DOPE or PEI22K (P¼0.0004 or 0.0121, respectively), Endostatin gene therapy on murine lung metastases model Y Nakashima et al though there were no differences in lung weight. No inhibition was observed in animals treated with the control plasmid.
Endostatin gene complexed cationic vector reduces tumor-induced angiogenesis
To evaluate the consequence of antiangiogenic therapy, we examined the lungs transfected on day 3 (Figure 4 ) histologically. Histological analysis by standard H&E staining and immunohistochemistry with an endothelial specific antibody against CD31 of the tumor regions showed decreased vascularization in the pST2-Endotransfected animals as compared with the controls (Figure 6 ).
Survival of mice bearing lung tumors that received endostatin or control gene transfer
Mice (n¼5 for each group) were injected with NFSa Y83 cells. Three days later, mice received PEI22K complexed with 60 mg of pST2-Endo or pST2, or saline alone into the tail vein at day 3 after tumor inoculation ( Figure 7 ). Mice transfected with pST2-Endo survived significantly longer than the control animals.
Discussion
Antiangiogenesis therapy has been suggested to inhibit the growth of cancers in vitro and in vivo. In this study, we have used cationic vector-mediated endostatin gene transfer in mice injected 3 or 7 days before with fibrosarcoma cells (NFSa Y83, 5 Â 10 5 ) which are highly metastatic to the lung. A single injection of the endostatin gene complex significantly inhibited the formation of lung tumors (Figures 6 and 7) and prolonged the survival of the mice compared with control mice (Figure 8 ).
There are various ways to deliver genes with potential tumor suppressing function to the lesion. There have been some reports on local injection of genes or vectors to the tumor directly. 17, 28 We selected a whole lung transfection method using intravenous injection with cationic vectors. The mechanisms of transfection with cationic vectors are already reported elsewhere. 38, 39 Administered DNA/cationic vector complexes via the tail vein are expected to reach pulmonary capillary endothelium before being captured in the liver. 36, 37 This method can affect the whole lung and is probably the best way to treat multiple pulmonary metastases. Using reverse transcription-polymerase chain reaction (RT-PCR), Western blotting and immunohistochemistry, we have shown that the introduced gene was efficiently Figure 7 Effect of endostatin gene transfection on survival of mice using the lung metastases model. At day 3 after tumor inoculation (arrow), the mice were injected with PEI22K complexed with 60 mg of pST2-Endo (*) or pST2 (&), or saline alone (K) into the tail vein. Survival was analyzed using the Kaplan-Meier method (5 mice per group). Statistical significance was tested by log-rank analysis (pST2-Endo compared with saline and pST2, P ¼ 0.0197 and 0.0184, respectively). Endostatin gene therapy on murine lung metastases model Y Nakashima et al transcribed ( Figure 4 ) and the protein was produced (Figures 1, 2 and 5 ). The expression was high in the lung which was the target of the fibrosarcoma cell implantation used in this study. Viral vectors, on the other hand, have been shown to be captured mostly in the liver. [40] [41] [42] We have measured the serum endostatin levels in mice 24 h after pST2-Endo transfection using enzyme-linked immunosorbent assay (ELISA) kits (CHEMICON). There was no significant elevation in pST2-Endo-transfected mice compared with untransfected control animals (not shown). It was suggested that the production of endostatin was not high enough to elevate the serum endostatin levels, and the effect we observed was due to endostatin produced and acted locally. This result is similar to the reports using other nonviral delivery systems. 4, 27 In a separate experiment, we have also shown that NFSa Y83 cells stably transfected with the endostatin gene and secreting endostatin (Figure 1 ) are less potent in forming lung tumors than the parental cells or cells transfected with the vector only (Figure 3 ), which may suggest the importance of the local production of endostatin.
The endostatin gene transfer was given once on day 3 or 7 after the intravenous fibrosarcoma cell inoculation. The mice that received the endostatin gene on day 7 of the inoculation bore more numbers of tumors than those that received the complex on day 3. This may suggest that the effect of endostatin gene is exerted better at the early period of tumor development. Bergers et al 43 reported the effect of antiangiogenic proteins at three distinct stages of pancreatic islet cell carcinoma in RIP1-Tag2 transgenic mice, ie: (1) hyperplastic stage (prevention trial); (2) small solid tumor status (intervention trial); and (3) substantial tumor burden (regression trial). Endostatin was shown to be significantly effective as prevention and intervention modality, although it failed to affect the tumor that has grown to a substantial size. We could not directly demonstrate the suppression of angiogenesis by the product of the transfected endostatin gene. Further analysis is warranted to determine the mechanism of tumor suppression in our system.
Although the endostatin gene transfection significantly reduced the tumor burden, the mice eventually succumbed to the lung tumor ( Figure 7 ). Many other alternatives are possible and we are planning to alter the timing of the endostatin gene transfer or search for a method to obtain sustained in vivo endostatin production to achieve tumor dormancy.
Materials and methods pST2-Endo construct
Total RNA was extracted from frozen 3-week-old C3H mouse liver using ISOGEN (Nippon Gene, Toyama, Japan) and treated with Moloney murine leukemia virus reverse transcriptase (SUPERSCRIPT II; Life Technologies, Gaithersburg, MD, USA). A cDNA coding for the mouse endostatin was amplified by PCR using two oligonucleotide primers (5 0 -GGGGTACCCATACTCAT-CAGGACTTTCAGCCA-3 0 and 5 0 -CGGAATTCCTTTG-GAGAAAGAGGTCATGAA-3 0 ). These primers introduced KpnI and EcoRI restriction sites at the 5 0 and 3 0 ends, respectively. A standard PCR protocol was used.
PCR-amplified cDNA fragment and the pSecTag2 (Invitrogen, Carlsbad, CA) were digested with KpnI and EcoRI, and then ligated to one another. This plasmid was designated pST2-Endo. The parent plasmid pSecTag2, pST2 was used as control plasmid. DNA sequence analysis confirmed that the mouse endostatin cDNA sequence was inserted in the proper reading frame and without mutations.
Cell lines and animals
COS-7 cells were obtained from the RIKEN Cell Bank (Ibaragi, Japan) and were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 2 mM Lglutamine. The murine fibrosarcoma cell line NFSa Y83 was kindly provided by Dr Koichi Ando (National Institute of Radiological Sciences, Chiba, Japan) and was maintained in MEM supplemented with 10% FBS. Male 7-9-week-old C3H mice were purchased (Chubu Kagaku, Nagoya, Japan). Research was conducted according to the Guideline for the Care and Use of Laboratory Animals of Nagoya City University Medical School. Experimental protocol was approved by the Institutional Animal Care and Use Committee of Nagoya City University Medical School.
In vitro transfection
Subconfluent COS-7 cells were transiently transfected on a 100-mm dish with a mix of 3 mg of plasmid DNA and 9 ml of FuGENE6 (Roche Molecular Biochemicals, Indianapolis, IN, USA) in 7 ml of DMEM + 10% FBS. After 4 h, the transfection medium was aspirated and replaced with DMEM + 10% FBS. Cells were cultured for 48 h, and medium was collected for Western blot analysis.
Generation of stable transfectants
Endostatin transfectants were generated by transfection of pST2-Endo into murine NFSa Y83 cells using FuGENE6 (Roche) following the manufacturer's instructions. Two days after transfection, the cells were placed under Zeocin (Invitrogen) selection at 2000 mg/ml. Four weeks after transfection, Zeocin-resistant colonies were expanded and cultured for 72 h. The conditioned media were collected, cleared of cell debris, and concentrated 10-fold with Microcon YM-10 column (Amicon Inc., Beverly, MA, USA) with an M r 10 000 cut-off for Western blot analysis. Control transfectants pST2 were generated in a similar manner.
Western blot analysis
The samples were subjected to electrophoresis under reducing conditions on a 12% polyacrylamide gel.
Proteins were transferred onto a polyvinylidene difluoride membrane (BIO-RAD, Hercules, CA, USA). The membranes were soaked overnight at room temperature in a blocking buffer (0.05% albumin, 5 M NaCl and 1 M Tris-HCl, pH 7.6) with 0.05% sodium azide, and then incubated for 2 h with a rabbit polyclonal anti-c-myc antibody (Santa Cruz, CA, USA) diluted to 0.1 mg/ml or rabbit polyclonal anti-mouse endostatin antibody (CHE-MICON, Temecula, CA, USA) diluted to 16.7 mg/ml. After washing, the membranes were incubated for 30 min with a secondary anti-rabbit horseradish peroxidase-conjugated antibody (Transduction Laboratories, PEI22K (Exgen 500; Euromedex, Souffelweyersheim, France), a 22 kDa linear form of polyethylenimine, was purchased. Plasmid DNA and PEI22K were diluted into 5% w/v glucose solution and vortexed. After 10 min, the solutions were mixed and vortexed. Twenty minutes later, 60 mg plasmid DNA complexed with PEI22K at an N/P equivalent of 4 in 250 ml 5% glucose were injected via the mouse tail vein.
Quantitative RT-PCR
Exogenous endostatin messenger RNA was assessed with a quantitative reverse transcription polymerase chain reaction (RT-PCR) method using LightCycler (Roche Molecular Biochemicals, Mannheim, Germany). Twenty-four hours after intravenous transfection, the animals were killed and the lung, heart, liver, spleen and kidney were harvested. The samples were homogenized and RNA was extracted using ISOGEN (Nippon Gene, Toyama, Japan). Any residual DNA was removed from RNA by incubating the RNA extract with RNase-free DNase I. One microgram of RNA was reverse transcribed by SUPERSCRIPT II with 0.5 mg oligo (dT) [12] [13] [14] [15] [16] (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA). The reaction mixture was incubated at 42 o C for 50 min followed by incubation at 72 o C for 15 min. Reaction mixture (0.1 ml) was used with LightCycler FastStart DNA Master SYBR Green I kit (Gibco BRL, Gaithersburg, MD, USA). Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression was used as a control of internal gene expression. The PCR primers coding exogenous endostatin were designed including the Igk-chain leader sequence located forward the flame coding endostatin to distinguish endogenous endostatin or collagen XVIII. The GAPDH PCR primers were designed by OLIGO software from previously reported mouse GAPDH. The cycling conditions in both GAPDH and endostatin PCR were as follows: initial denaturation at 95 o C for 10 min, followed by 50 cycles at amplification consisting of 15 s at 941C, 5 s at 561C and 20 s at 721C.
Immunohistochemistry
At 24 h following intravenous transfection, the lungs were reperfused through the heart with 10 ml of saline solution. Lungs were removed by dissection, and cut to small tissue blocks. The lung tissues were cultured on a 100-mm dish with 2 mM of monensin/ethanol solution for 3 h for the purpose of blocking protein secretion. The tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and cut into 6-mm sections. The tissue sections were deparaffinized using xylene and rehydrated in a graded series of alcohol with a final wash in distilled water. Sections were then quenched in methanol with 0.3% hydrogen peroxide for 10 min, blocked for 30 min in 5% (w/v) nonfat dry milk, and incubated at 41C overnight in rabbit polyclonal anti-c-myc antibody (Santa Cruz) diluted to 2.5 mg/ml in PBS. Subsequent detection was by HISTOFINE SAB-PO Kit (Nichirei, Tokyo, Japan) according to the manufacturer's instructions with modifications. Sections were incubated in biotinylated secondary anti-rabbit antibody (10 mg/ml) for 10 min, rinsed in PBS, and then incubated in a solution containing streptavidin-horseradish peroxidase for 5 min at room temperature. A solution containing 3,3
0 -diamino-benzidine-tetrahydrochloride (MERCK, Darmstadt, Germany) and 0.2% hydrogen peroxidase was used as the chromogen. Sections were counterstained with hematoxylin, dehydrated, and mounted. The lungs from nontransfected mice were used as negative control. For CD31 immunostaining, mice were intravenously transfected 3 days after fibrosarcoma cell implantation and killed after 14 days of tumor inoculation. Frozen sections of the lungs were cut and then subsequently fixed in acetone for 10 min. After quenching and blocking, the sections were incubated with 1 : 800 dilution of a rat anti-mouse CD31 monoclonal antibody (PharMingen, San Diego, CA, USA) at room temperature for 1 h, followed by a biotinylated rabbit anti-rat antibody (10 mg/ml). Serial sections of each tumor were also stained by hematoxylin/eosin (H&E) staining.
In vivo evaluation of lung metastases and treatment
Experimental lung metastases were established in mice by injecting 5 Â 10 5 NFSa Y83 cells in 100 ml of saline solution into the tail vein of C3H mice (n ¼ 10 per group). Three or 7 days after tumor cell implantation, the mice were injected intravenously 60 mg of pST2-Endo or control pST2 plasmid complexed with either GL67/ DOPE or PEI22K. Two weeks after tumor cell implantation, the mice were killed and examined for lung metastases. The organs were fixed in 10% buffered formalin prior to being weighed and photographed.
Statistical analysis
In tumorigenesis experiments, data were analyzed by the two-tailed unpaired Student's t-test, using the StatView 5.0 software program. Survival curves were calculated by the Kaplan-Meier method and compared with the logrank test. Statistical significance was set at P o 0.05.
